1. French National Institute of Health and
Inserm
French National Institute of Health and
Medical Research
Created in 1964 from the National Institute of Hygiene and Hospital Research
Working through the
Ministries for Research and Health

2. (62% of total budget dedicated to salaries)
Inserm : key figures
335 Inserm laboratories
19 research centers
41 Clinical Investigation Centers (CIC)
Budget 2006 : 700 M€
Total staff:
(2 500 physicians) of which
5 100 Inserm employees
(62% of total budget dedicated to salaries)
An active patent portfolio of 572 families
374 French and foreign firms are partners of Inserm
56 start-up companies based on Inserm technology

3. What is Inserm ?
The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public Health
All fields of research are covered in these domains
80% of the 354 research units are located in University hospitals
Research units with 8 years mandate with mid-term (4 year) evaluation. Stringent evaluation
Investigator- driven projects - AVENIR programme
Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.

5. Inserm’s share (%) of publications in France Publications 1995-2005

7. Inserm publishing visibility (1995-2005)
% publications
Number of citations

8. Inserm Affiliations

9. Field Evolution (publications 1995 – 2005)

10. Evolution of the clinical medicine field (publications 1995 – 2005)

11. Science (IF=30,927) and Nature (IF=29,273)
Que les articles, ni lettres ni revues
New England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)
Science (IF=30,927) and Nature (IF=29,273)

12. The Inserm performance bibliometric analyses

15. Science (IF=30,927) and Nature (IF=29,273)
Que les articles, ni lettres ni revues
New England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)
Science (IF=30,927) and Nature (IF=29,273)

16. Organization
Bottom-up initiatives: selection based on quality and innovation
Networks focused on major public health issues

17. Cardiovascular Bone and Joint Diseases 2.2% Diabetes 2.6% Hepatitis
3.1%
Genetic
diseases
10.5%
16.8%
Cancer
Cardiovascular
9.1%
17.1%
Immunology
of which 9.3%
for neurologic
disorders
20.6%
Neurosciences
Infectious diseases
and microbiology
(without Aids and Hepatitis)
8.3%
Public health
7.5%
Handicap
5.1%
Nutrition
4.8%
AIDS
3.7%
Research laboratories being often involved in more that one domain, the overall distribution is over 100 %

18. « Interdisciplinarity »
Inter-research agencies programmes :
- CNRS : SPI, STIC, chemistry, etc..
- INRIA
Dedicated research units in specific infrastructures:
ex: CNG, Nanotechnology
Dedicated research Programmes :
- Nanotechnology
- « Systems biology »
Training

19. Inserm : creation of research centers
Objectives and main characteristics:
Critical mass (100 to 300 staffs),
Mutualisation and Integration
International visibility, Attractiveness
Assessment criteria:
Scientific excellence
Quality of the management :
Governing structure, mutualised administration & management
Technology transfert and research outcomes
Sharing of technical facitilies
Coordination of scientific events and programmes
Implementation of research training programmes
International scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)

20. 19 Centres de Recherche
au 1/07/2007

21. 19 Research Centers in 2007 1- Paris 6, Pluri-thematic
Some exemples:
1- Paris 6, Pluri-thematic
2- Paris 6, Neurophysiology
4- Paris 5, Pluri-thematic
5- Créteil, Pluri-thematic
6- Lilles, Pluri-thematic
7- Dijon, Cancer/Nutrition
8- Bordeaux, Neurophysiology
9- Grenoble, Neurophysiology
10- Grenoble, Cancer
11- Toulouse, Pluri-thematic

22. Evolution des unités et CDR entre 2001 et 2007

23. (Universités, Hôpitaux)
Infrastructures de recherche
CNRG:
CNS, CNG, RNG
Unités De
recherche
Régions
EUROPE
7e PCRDT
ESFRI
R.I.O:
Inserm, CNRS, CEA, INRA
(Universités, Hôpitaux)
IFR
« Grosses » infrastructures: P4 (Lyon)
ICS (Strasbourg)
Mircen (Fontenay: CEA-Inserm)

24. Research infrastructures
National Genomic Research Consortium: CNRG
National Sequencing Center
National Genotyping Center
Regional Genopoles Core Facilities
Biosafety-level 4 laboratory
Local and regional technological plateforms
Clinical Research Infrastructures

25. Regional clusters
Canceropoles, other thematic poles (Neuropole, …)
Competitivity clusters (Industry)
Regional poles for research in Neurosciences, etc.

26. Biotherapies, Neurosciences
Competitivity Clusters
67 created clusters
7 involving Inserm units
International
National
Emergent
Virology
Nutrition, Ageing
Imaging, Cancer,
Biotherapies, Neurosciences
Biotherapies
Cancer, therapeutics
Therapeutic innovation
Nutrition

27. 10 National & 23 Regional infrastructures
National infrastructures :
Regional infrastructures :
Animal experiments
Functional investigations
Transcriptomics
Proteomics
In vivo imaging
Structural biology
Cellular imaging
Sequencing
Electron microscopy
Lille
Rouen
Caen
Paris
Nancy
Strasbourg
Rennes
Orléans
Dijon
Nantes
Lyon
Bordeaux
Grenoble
Clermont-
Ferrand
Poitiers
Nice
Toulouse
Marseille
Montpellier 1
Rousset 2 3
10 National
&
23 Regional
infrastructures

28. Main Inserm’s priorities
« Researchers » : Careers, Training & Mobility
To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach
To establish Inserm in a European and International context
To develop public/private partnerships

29. Career, Training and Mobility
Researchers :
Career, Training and Mobility

30. NEW CAREER TRACKS General principles
To strengthen the status of young scientists; to recognize, evaluate and promote scientific qualities: high level fixed term contracts and the program AVENIR
To offer tenure positions to researchers: mid and long-term research plans
To increase research career development and mobility and foster partnerships:
INTERFACE RESEARCH GRANTS

31. Le recrutement chercheur
Contrats jeunes chercheurs « Juniors »:
5 ans (évaluation intermédiaire à 3 ans)
30%: Avenir
Suivi: mission chercheurs
Chargés et Directeurs de recherche
Contrats post-doctorants 12 mois (24 mois ?)
(Postes verts)

32. Post-doctoral career track Inserm-NIH (appel d’offres permanent)
Candidats proposés par l’Inserm après leur thèse:
3 ans de post-doctorat dans l’un des instituts des
NIH « intra-muros ».
Suivi personalisé (mission chercheurs), évaluation
de la qualité du stage post-doctoral
Contrat Junior (5ans, avec évaluation à 3 ans)
Contrat temporaire universitaire ou HU
Recrutement: EPST, Université etc ..

33. (Labos internationaux)
Contrats d’interface pour chercheurs et ingénieurs de recherche
Hôpital
CHU, CLCC
383
Industrie 6
Université 60 CR DR IR
Internationaux
(Labos internationaux) 2
Agences Sanitaires
N: 5
Inserm (ISFIC)
Chercheurs: 50
Ingénieurs: 37

34. Contrats d’Interface Médecins hospitaliers et HU et Enseignants-chercheurs
HOPITAL
INSERM
88 PH, MCU-PH,
PU-PH
UNIVERSITE
INSERM
11 enseignants-chercheurs

35. Career tracks in Inserm
Junior, temporary (5years with 3year intermediate
evaluation), high level contracts
Avenir program
European programs: EURYI, ERC
Permanent positions for senior scientists

36. AVENIR Programme
Eligibility: Young scientists with permanent or temporary position, clinicians
Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities
Each successful candidate is allocated:
A yearly budget of 60 K euros
Minimum lab space of 50 m2
Personnel: 1 post-graduate collaborator and 1 graduate student
Each successful young scientist receives a salary for 5 years

37. Tenure career track: General principles Academic freedom
Design tenure career tracks with reasonable security:
Academic freedom
Reinforce interface with partners: intersectoral mobility:
Hospitals: clinical research, health policy issues
Health agencies
Universities: teaching, making scientific information
available to the society
- Industry: technological transfer and valorisation
European mobility ?

38. Interface contracts : General principles
Based on :
a permanent position + temporary, 3-5 year contracts
To reinforce interactions with partners and mobility
Hospitals: clinical research, medical issues
Health agencies: health policy issues
Universities: teaching, making scientific information available to the society
Industry: technological transfer and valorisation
European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)

39. Tenure position + 3-5 year contracts: " 2/3 – 1/3 "
New Career Track
Tenure position year contracts: " 2/3 – 1/3 "
Universities
Industry
University hospitals
Cancer centers CR DR
Inserm
DGS / Health agencies
International (Hospitals, universities)

40. David SASSOON Born on May 25, 1959 Presently : Professor of Molecular Biology, Mount Sinai Medical School , New York, USA
Joint Inserm/AFM/Paris VI operation
Research theme: muscle development
DR1 permanent position + interphase contract (AP-HP)
Inserm Unit
Chair of excellence 2004 (MR), Avenir
Laboratory space: 750 m2: Pitié-Salpêtrière hospital
Accompagnying measures:
- IR Paris VI
- Temporary contracts
Assistance with school, housing…

41. Thomas BAUMERT, M.D. Born on May Presently: Assistant professor, Dept of Medicine University of Freiburg, Germany
Inserm/ULP/HUS Strasbourg joint operation
Research theme: HCV
Laboratory: Virology laboratory in Strasbourg
DR2 permanent position + Interphase contract HUS
Inserm unit, Avenir: in progress
Temporary contracts
Assistance with school, housing…
PU-PH

42. Matthew ALBERT, M.D. PhD Born on December 9, 1970 Was: Clinical Scholar, Rockfeller University and Resident Clinical Pathology The New York Hospital New York, USA
Inserm/Pasteur Institute/Necker Hospital joint operation
Research theme: Dendritic cell biology/HCV/Cancer
Location: Pasteur Institute Paris
Since June 2003 : Inserm DR2 permanent position + Interphase contract AP-HP + Team Leader Pasteur Institute
Inserm Avenir Unit and Pasteur Institute Unit
Temporary contracts (junior scientists, MDs)
Assistance with housing

43. (62% of total budget dedicated to salaries)
Inserm : key figures
325 Inserm laboratories
19 research centers
41 Clinical Investigation Centers (CIC)
Budget 2006 : 700 M€
Total staff:
(2 500 physicians) of which
5 700 Inserm employees
(62% of total budget dedicated to salaries)
An active patent portfolio of 572 families
374 French and foreign firms are partners of Inserm
56 start-up companies based on Inserm technology

44. Interface Contract grants for MDs
Reinforce research activities of clinicians and university research assistants and professors
3-5 year contracts for clinicians : assistant professors and
professors, university employees
Grant paid by Inserm to hospitals and universities to be used for :
- clinical and teaching activities: temporary positions
- financing research activities

45. The School of Inserm
A 3 year Educational programme which leads to a Master and MD-PhD track
First year of Inserm School - Second year of Medical School :
Special School Intensive Training Session in February
June: Competitive Exam
Second year of Inserm School - Third year of Medical School
6 month full time Research Clerkship in an Inserm Research Laboratory
Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree

46. and Translational research strategy
Clinical research
and Translational research strategy

47. A continuum from Basic to Clinical Research:
Translational research
To develop dedicated performing Research Infrastructures
To sponsor clinical studies and innovative therapeutic clinical trials
To ensure appropriate training of Physicians to Research skills and vice-versa
To integrate these actions in a European context:
ECRIN, Biological resource centers: Roadmap ESFRI
Innovative medecine platform

48. Clinical trials Inserm Inserm Inserm Proof of concept Basic
Phases I-IIa
Biotherapy
Basic
Research
Preclinical studies :
Proof of concept
Phases
IIb-III
Phase IV
Cohorts
[CRC]

49. The new “challenges” of clinical research in Europe
To support development of new therapeutic molecules :
Innovative BASIC research approaches
Innovative CLINICAL research: therapeutic and physio-pathological studies
in between : dedicated research infrastructures
To support Innovation and Biotechnology sector development
To satisfy end-users (patients) requirements

50. Inserm, as a major actor of the Clinical Research in France and in Europe
To set-up an efficient Translational research towards the benefits of patients
To develop dedicated performing Research Infrastructures : ECRIN, GMP facilities platforms (innovative biomedicines), BRCs, (Roadmap ESFRI)
To sponsor clinical studies and innovative therapeutic clinical trials
To ensure appropriate training of Physicians to Research skills and vice-versa : School of Inserm
To built a continuum from Basic research to Clinical Research

51. Clinical research infrastructures
2006
2001
2002
2003
2004
2005
Clinical research centers 42 17 21 28 31
Tissues Banks 47 16 30
Cohorts
118
131
135
142
147
Registries 35 29
Networks 22 9

52. Infrastructures de recherche clinique Et en santé des populations
2006
< 2000
2000
2001
2002
2003
2004
2005
CIC
CIC-EC
CIC Biothérapie 23 7 11 41 10 17 21 + 24
Collections biologiques 47 - 16 30
Cohortes
147 99
117
131
135
142
Registres 29 31 35
Réseaux 26 9 22 35

53. Les CIC
CIC « généralistes »
CIC-EC: épidémiologie et gestion des essais cliniques
CIC-Biothérapie
2007: CIC-»innovations technologiques »

54. CIC et Unités Inserm
Promotions Inserm: 20% demandées par les CIC
Etudes et essais cliniques réalisées dans les CIC:
environ 20-30% viennent des unités

55. Budget de base + projets
Comment renforcer les collaborations?
Postes d’accueil
pour internes
Contrats chercheurs
Juniors 5 ans
Services de soins
et de biologie
CHU
Contrats d’interface
CIC
Equipes de recherche
Translationnelle
Budget de base + projets
Unités de recherche
Inserm

56. CIC, CIC-BT and CIC-EC (2006)
Bichat
Henri Mondor
(94 Créteil)
Pitié-
Salpêtrière
Necker Enfants Malades
Robert Debré
Saint-Louis
Saint-
Antoine
HEGP
Les
15-20
Cochin
IGR (Villejuif)
Lille
Rennes
Nantes
Tours
Nancy
Strasbourg
Lyon
Montpellier
Marseille
Bordeaux
Toulouse
Grenoble
Rouen
Saint-Etienne
Dijon
Brest
Clermont-Ferrand
Besançon
CIC (23)
CIC-EC (7)
CIC-BT (11)
Saint-Pierre
Ile de la Réunion

57. Key Figures of the Clinical Research
797 on-going Clinical trials
monocentrics
French multicentrics
European and international multicentrics
About patients expected to be included and currently involved
120 beds devoted to clinical trials
A staff of professionals
101 physicians, pharmacists,
27 biostatisticians, psychologists, researchers
69 nurses
51 Clinical research technicians, administrative

58. Thematic networks of CIC
Cardiovascular : 14 CIC Coordinator : F. Zannad, CIC de Nancy Metabolic diseases and diabetes : 9 CIC Coordinator : P. Petit, CIC de Montpellier Gastro-Enterology-Hepatology : 9 CIC Coordinator : C. Libersa, CIC de Lille Thrombosis : 3 CIC Coordinator : H. Decousu, CIC de St Etienne Cancer Coordinator : F. Calvo, CIC de St Louis (AO-HP) Neurosciences : 13 CIC Coordinator : Ph. Damier, CIC de Nantes Paediatric : 8 CIC Coordinator : E. Jacqz-Aigrain, CIC Robert Debré de Paris

59. National networks of Clinical Research Centres Clinical Trial Units
Pan-European network of Clinical research infrastructures: the ECRIN network of INSERM
ECRIN : European Clinical Research Infrastructures Network
National networks of Clinical Research Centres Clinical Trial Units
Sweden
SweCRIN
ECRIN should be considered as a tool that will allow:
- to access research facilities certified as compliant with the GMP/GLP standards in Europe
- to access expertise in the preparation and conduct of trans-national clinical trials
- to access scientific and ethic evaluations
Québec
FRSQ-GEREQ
Denmark
DCRIN
Germany
KKS
Other
networks
EFGCP
France
CIC & UEC
Spain
SCReN
Italy
CIRM & IRFMN

60. ECRIN : a Platform of Integrated services to multinational studies
Integrated services (one-stop shop) to multinational studies:
1 - interaction with ethics commitees
2 - interaction with competent authorities, regulatory affairs
3 - drug dispensing
4 - adverse event reporting
5 - data management
6 - study monitoring
7 - management of biological samples

61. Biological Resources Centres a networking action at both National and European Levels

62. Lille
Caen
Rennes
Nantes
Tours
Nancy
Strasbourg
Lyon
Montpellier
Marseille 3 2 1 9
Dijon
Grenoble
Toulouse
Amiens
Angers
Brest
Reims 36
IDF
BRCs in France National policy of the Ministry for Research and the National Research Agency to support the development of BRCs

63. Biological Resources Centres
Key components to:
Industry : external sourcing: innovative targets, hits and leads, biomarkers, clinical studies…
Academic : valorisation, technology tranfer and dissemination of knowledge.

64. Biological Resources Centres
"Service providers and repositories of the living cells, genomes of organisms, and information relating to heredity and the functions of biological systems" (O.E.C.D. definition).
Infrastructures that qualify biological samples (DNA, RNA, proteins…), provide samples for national projects and keep samples for the future (inheritage).

65. European Biological Resources network (EBRC)
The necessity of a European network :
To co-ordinate European scientific programs and policies : 7th PCRD
To develop and harmonize assurance-quality standards for European BRCs : exchanges of authenticated biological materials.
Valorisation of knowledge
Attractiveness of public research and development of innovative SMEs.

66. The European BRCs brings together:
Service and work facilities made up of collections that satisfy the EU research objectives
Conservation sites made up of patrimonial reference collections : national collections, cryobanks, rare tissue or tumour collections…
Ongoing European initiatives :
Contact at Inserm :

67. From Cohorts to Biomarkers
Cohorts : key issues for Inserm
Access to "thematic" cohorts of patients (cancer, mental diseases, etc.)
Access to cohorts of healthy volunteers for prospective studies, genetic studies, etc.
The Challenges of Biomarkers
Clinic : prediction, diagnostic and prognosis
Bio-pharmaceutical industry : Valorisation of Research in partnership with industry.

68. Platforms for GMP production
State of the art :
Platforms for production of therapeutic vectors : Nantes (Atlantic biothérapies), Généthon, etc.
Platforms for production of bio-medicines : LFB, Genopole Ile-de-France, Vivalis, Lipidomix, etc.
Platforms for production of therapeutic virus : Heidelberg
Perspectives : availability of GMP products
Partnership with Inserm-Transfert
Costs sharing
European dimension : ESFRI / IMI

69. IMI : Innovative Medicines for Europe
European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way.
Inserm is the French representative in the Member states contact Group of IMI

70. Organization
Bottom-up initiatives: selection based on quality and innovation
Networks focused on major public health issues

71. National Research Programs
To bring together all parties interested in a given research area:
Research institutes
Universities
Hospitals
Sanitary Agencies
Charities and Foundations
Medical Societies
Social protection agencies
Patient Associations
Industry
To launch calls for proposals open to the scientific community regardless of institutional affiliation
To support young investigators, scientists and clinicians

72. National Research Programmes
Main missions of the Inserm National Research Programmes :
To support new/young research teams
To support organisation of seminars and workshops : prospective studies and follow-up of actions
To identify projects that could be submitted to FP7 or some other international programmes (NIH, etc
Collaborations with the NIH: seminars and grants
To reinforce partnerships with
Patients associations
Medical specialised scientific societies
Industry

73. National Research Programmes
National Research Program on Cardiovacular Diseases PNRC
National Research Program on Diabetes PNRD
in collaboration with CNRS
National Research Program on Human Nutrition PRNH
in collaboration with INRA
National Research Program on Bone and Joint Diseases PRO-A
Virtual Institute for Public Health Research IVRSP
National Research Program on sense organs PNRV

74. ANR,INCA ANRS….. National Research Programs Networks
Projects
ANR,INCA
ANRS…..
National Research
Programs
Networks
PNRD
PNRC
PRNH
ATC BIOTHERAPY
ATC DRUGS
SYSTEMS BIOLOGY
ATC ALCOHOL
PRO-A
IVRSP
PNR-Dermato
PNR-O. Sens
PNR-Hépato-GE
PNR-Endo-Repro
EUROPE
NIH
Missions:
Recruitments:
Avenir etc.
Research structures:
centres
Projects: cohorts etc..

75. National Research Agency (ANR)
Created in February 2005 with a total yearly budget: around 800 M€ (approx. 25 % dedicated to Biomedical sciences)
Main objectives :
support to basic research projects
support to translational research (partnerships)
Launched calls for thematic and "free" programmes :
Cardiovascular diseases, Obesity, Diabetes
Neurosciences, psychiatry
Microbiology- Immunology
Rare diseases
Projects of scientific excellence : 370 k€ for a 3-year duration and involving 3 to 4 partners (in average)

76. National Research Agency (ANR)
Main figures in 2005:
35 calls for proposals published
5652 proposals submitted
Success rate : 25,7% => 1454 projects / 4500 research teams
Breakdown of budget available / scientific domains :
30% Non-thematic
25% Matter and Information
19% Biology and Health
18% Sustainable energy and environment
8,8% Ecosystems and sustainable development
Specific actions and support to Partnership & Competitiveness, Young researchers (including chairs of excellence)

77. Inserm - ANR Programme Management
Launch of the Thematic programme "Biology and Health"
In Cardiovascular, Obesity, Diabetes
Neurosciences, neurology and psychiatry
Microbiology - Immunology
Rare diseases
Health and environment
Health technologies
Emerging and maturation of biotechnology projects
In Physio-pathology of human diseases
Microbiology- Immunology- Emerging diseases
Research and Innvovation in Biotechnology Emerging and maturation of biotechnology projects
Biological Resources sampling in Health

79. The European and International cooperations

80. The European policy of Inserm

81. The main axes EU Prospectives (ESF, EUROHORCS, etc.)
Participation in European programmes : RTD FP & Public Health FP
Infrastructures - ESFRI (ECRIN, …)
Researchers’ mobility within EU programmes and
Bilateral actions: Common Research projects - Associated laboratories - Joint-units abroad

82. Multilateral cooperation actions
Participation to the European Research and Public health programmes
Inserm and
The 6th Framework Programme of the EU
Inserm and
The 7th Framework Programme of the EU
( )

83. CANCER 7 inter-regional “Canceropoles”

84. Inserm-Transfert SA
Private subsidiary of the French National Institute for Health and Medical Research (Inserm)
Created by Inserm in 2001, funded up to 4,5 M€ by Inserm and comprising actually 50 people
Increase researchers’ awareness of technology transfer and company creation
Identification and promotion of innovative projects emerging from Inserm’s laboratories
Launch of a new seed fund called “Inserm-Transfert Initiative” with three major investors in the biotech field (Sofinnova, Ventech, CDC Entreprise) - Capital amount = 4.2 M€

85. International project management
21 projects under management (6 Network of Excellence, 3 Integrated Projects, 12 STREP) and 8 projects under negociation
Total budget for all projects under management over 200 million €
Creation of value by up-coming licensing and SME’s participation
Biotech start-up creation and Patenting
Inserm-Transfert has invested 800 kEuros in 11 new biotech companies that have raised 85 million euros
600 patents' family - 60 to 90 New demands/year licensing agreements

86. Bilateral cooperations’ actions
Researchers' mobility (short-medium term, Interface Contract grants)
Research networks ( EU programmes , NIH, Bill Gates etc..)
Associated laboratories
Joint Research unit abroad

87. Bilateral cooperations’ actions
Researchers' mobility (short-medium term, Interface Contract grants)
European research networks at the bilateral level and within the EU programmes
European Associated laboratories
Joint Research unit abroad

88. Cooperations between Inserm and German Partners (1)
One formal agreement with DFG : short-term exchange of researchers based on 2 years projects
538 cooperation undertaken since 1985
Main city: Berlin, Bonn, Munich, Freiburg, Heidelberg
Main thematic areas : Cellular Biology,Neurosciences, Immunology, Cancer, Genomics, Cardiovascular diseases,…
51 German Post-doc, Researchers and Fellows in the Inserm's research units in 2005
Cooperation with Freiburg:
35 projects, mainly in dermatology, neurosciences, virology, toxicology, etc

89. Cooperations between Inserm and German Partners (2)
Associated laboratories under preparation (HEGP/La Charité - Freiburg/Strasbourg)
A Joint Unit Abroad - U701 Inserm / DKFZ (J. Rommelaere - Heidelberg) - Cancer and Virotherapy
In the frame of the 6th EU Framework programme :
59 European research projects mainly in the LSH priority : 16 NoE - 27 IP - 14 STREPs - 2 CA (84 Inserm's teams - 83 German teams
Future collaborations within the FP7 :
Health priority, IMI, Infrastructures (ECRIN, BRCs)

90. Cooperations between Inserm and Hungarian Partners (1)
40 cooperation projects undertaken since => more than 61 common publications
Main cities: Budapest, Szeged, Debrecen
Main Partner Institutions : Hungarian Academy of Sciences, Semmelweis University, University of Debrecen etc.
Main thematic areas : Neurosciences, Cellular Biology, Molecular Biology, Cardiovascular Physiopathology, Biochemistry…
10 Hungarian Post-docs, Researchers and Fellows within Inserm's research units in 2005 90

91. Cooperations between Inserm and Hungarian Partners (2)
In the frame of the 6th EU Framework programme :
13 European research projects mainly in the LSH priority : 5 NoEs - 7 IPs - 1 STREP (17 Inserm's teams Hungarian teams)
Future collaborations within the FP7 :
Health priority, IMI, Infrastructures (ECRIN, BRCs) 91

92. Bilateral cooperations’ tools
Associated Laboratory
Inserm Unit Abroad
Scientific driven
2x4 years mandate
Synergies: competencies and facility access
Co-funding by Inserm and Associated partners
Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)
Networks, EU research projects

93. Bilateral cooperations’ tools
European Associated Laboratory
Inserm Unit Abroad
Scientific driven
2x4 years mandate
Synergies: competencies and facility access
Co-funding by Inserm and Associated partners
Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)
EU research projects - Networks

94. European Associated laboratory (LEA)
Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles)
Lille : M. Capron U547 / Bruxelles : M. Goldman (IMI)
Joint Research Unit in Europe:
Université de Glasgow / C. Doerig U609
DKFZ / J. Rommelaere U701
Associated laboratories
(under preparation)
Milan / Bordeaux
Rome / Villejuif
Rome / Nice
Ferrara / Paris
Dundee / Toulouse
Freiburg / Strasbourg
Berlin / Paris
Barcelona / Paris
Porto / Toulouse
Dundee
Glasgow
Bruxelles
Berlin
Freiburg
Heidelberg
Prague
Milan
Barcelona
Ferrara
Porto
Rome

95. European Associated Laboratories (LEA)
Toulouse  Prague:
D. Langin (Inserm U586) - V. Stich (Univ. Charles)
Lille  Brussels:
M. Capron (Inserm U547) - M. Goldman (Univ. Libre de Bruxelles)
Toulouse  Dundee:
AC Prats (Inserm U589) - JC Bourdon (Univ. Dundee)
Bordeaux  Milan:
A. Bikfalvi (Inserm E 113) - L. Bello (Univ. Degli Studi)
Nice  Rome:
G. Meneguzzi (Inserm U 634) - G. Zambruno (IDI-IRCCS)
Villejuif Paris Sud  Rome:
D. Samuel (Inserm U 785) - M. Levrero (Univ. La Sapienza)
Montpellier  London:
K. Ritchie (Inserm U 888) - G. Thornicroft (King’s College of London)
Strasbourg  Freiburg:
T. Baumert (Inserm U 748) - H. Blum (Univ. of Freiburg)
Villejuif Paris Sud  Barcelona:
T. Moreau (Inserm U780) - J. Antό (PRBB, IMIM-CREAL)
Bordeaux  Porto:
L. Bordenave (Inserm U 577) - M. Barbosa (IBMC, INEB)
Dundee
Glasgow
London
Brussels
Heidelberg
Prague
Freiburg
Milan
Porto
Barcelona
Rome
Joint Research Unit in Europe:
Glasgow University / C. Doerig (Inserm U609)
DKFZ / J. Rommelaere (Inserm U701)

96. Montreal
Laval
Montréal
Los Angeles
Seoul
Beijing
New York
Haïfa
Tokyo
Rabat
Wuhan
Irvine
Pittsburgh
Kyoto
Nanjing
Dallas
Shanghai
Doha
Guangzhou
Singapour
Rio de Janeiro
INSERM Unit
Associated Laboratory
In preparation
Buenos Aires

97. “2/3 base salary + 1/3 supplementation”
« European and International Interface Contract » grants ?
Pilot action under preparation
Permanent position by Inserm + temporary contract:
“2/3 base salary + 1/3 supplementation” 

98. Japan is the first partner of Inserm in Asia (ca
Japan is the first partner of Inserm in Asia (ca. 180 collaborative projects).
An increase between 2000 and 2006 (+40%).
About 20 Japanese scientists within Inserm units each year.
2% of Inserm publications are with Japan.
Long term relationship Inserm-JSPS : 80 projects funded since 1994
Inserm-Japan

99. Inserm-Japan : New Avenues of Collaborations
International Associated laboratory with the RIKEN DRI on lipidomics study of membrane microdomains.
Inserm Unit in Kyoto University Graduate School of Medicine on trans-ethnic comparative human genomics
A clinical research partnership between Inserm and its partners and the Translational Research Center of Kyoto University.
A collaborative agreement with the Riken so as to foster our partnership in :
Stem cell biology (Riken CDB)
Immunology (Riken RCAI)
Neurosciences (Riken BSI)

100. Inserm International Laboratories and Inserm Unit in Japan
Tokyo
Tokyo
Kyoto
INSERM Unit
Associated Laboratory
In preparation

101. Evaluation of participation of Inserm to the 6th FP as in March 2006
Inserm is involved in 99 projects (including coordination of 24 projects)

102. Accompanying measures of Inserm
Project preparation mainly within the FP6 programme : partnership with Inserm Transfert SA
The « Europe Task Force » actions:
Information and promotion
Pre-evaluation of potentiaI EU projects
Coordination / partnership of Inserm
S&T, administrative, legal and financial follow-up
Follow-up of the next FP7 (Thematic priorities, JTI, …)

103. Missions of the European Affairs division of the DPRE
Information
European project preparation and follow-up, in close collaboration with Inserm-Transfert (the private subsidiary of Inserm)
To represent Inserm at Brussels and near other European institutions
To follow European policies development and to evaluate opportunities
To set-up and coordinate bilateral cooperations

104. The European Affairs division
A dedicated Team
Contact person in each connected/involved Inserm’ departments: The EUROPE Task Force
A permanent staff in Brussels (CLORA)
A contact in London
A competence centre in Project management within Inserm-Transfert
A specific budget

105. The « Europe Task Force » of Inserm
DRI
DRCT
- Lobbying - Information
- Marie-Curie programme
- Training sessions and information targeted to:
Administrative staffs
Projects' coordinators
Consortium agreements
Preparation & management
of EU projects
Costs models
- Budgets - Contractual issues
Infrastructures
ERA-NETs - Ethics
CLORA
DG RESEARCH EC
Inserm's
Laboratories
Inserm Transfert
ADRs
DFL
DRH
Europe
Innovative
Start-up
DAPS
DPRE
Regional & National
Partnerships
European
Clinical research
JTI/IMI
END
- Bilateral cooperation - LEA/Unit abroad

106. Inserm-Transfert as the vector of Inserm‘s Technology Transfer
Universities
Inserm-Transfert
International
institutions
Pharmaceutical
companies
Biotech companies
Investors/ VCs
Inserm

107. Inserm-Transfert activities: forwarding science into business
Technology Transfer
& Licensing
International
Projects Management
Industrial Projects
Management
Proof-of-Concept
validation
Biotech Companies
creation
Sourcing &
IP Management

108. Career, Training and Mobility
Researchers :
Career, Training and Mobility

109. “2/3 base salary + 1/3 supplementation”
« European Interface Contract » grants ?
Pilot action under preparation with European institutions (Italy, Portugal, UK, Spain, Germany,..)
Permanent position by Inserm + temporary contract:
“2/3 base salary + 1/3 supplementation” 
Co-funding strategy : one of the European Marie Curie schemes ?

110. Extension of such programs to European mobility - Marie Curie Fellowship scheme ?
Heterogeneity of scientists career tracks: tenure positions provided by universities vs. research agencies etc…
However: the senior positions offered by each country may be viewed as a “core” status which salary can be maintained by the institution for scientists who wish to work in other countries.
As an incentive to mobility, the host institutions might add temporary grants (Interface grants) obtained by the scientist who moves to another country, provided by: hospitals, universities, industry, others…
Basis of the program: reciprocity, attractivity …
Future prospective :
a more "homogenized" tenure position career track: (salary, social security benefits and taxes, EU-wide health card etc.)
- Implication of European Marie Curie programs ?

111. Inserm’s web site : www.inserm.fr
Contacts :
Inserm’s web site :
Department of French Regional and European Strategic Policies
Anne Bisagni, Director :
Philippe Arhets, Deputy Director :
Cécile Bergouignan, Bilateral cooperation :
Human Resources : Researchers task force
Anne-Marie Laffaye, School of Inserm, Avenir :
Richard Salives, Marie Curie Programme :

112. « Le concert », Nicolas de Staël, 1955